AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14991374 — intervention group
Group type: COMPARATOR
Intervention: Risperidone and placebo
Number of subjects: 50
Study 11229946 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified consent form (MF)
Number of subjects: 100
Study 11229946 — intervention group
Group type: COMPARATOR
Intervention: Standard industry consent form (IF)
Number of subjects: 100
Study 9513749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) infusion of TRP 100 mg/kg
Number of subjects: 38
Study 9513749 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 38
Study 7921460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 109
Study 7921460 — intervention group
Group type: COMPARATOR
Intervention: T-piece trials
Number of subjects: 109
Study 7921460 — intervention group
Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 109
Study 3050616 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (800 mg/i.v.)
Number of subjects: 2250
Study 3050616 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (15,000 UI/s.c.)
Number of subjects: 2250
Study 3050616 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (800 mg/i.v.) and Calcium heparin (15,000 UI/s.c.)
Number of subjects: 2250
Study 31619463 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib 0.4 mg/kg
Number of subjects: 63
Study 31619463 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib 0.8 mg/kg
Number of subjects: 63
Study 31619463 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib (both doses)
Number of subjects: 63
Study 31619463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (all grade)
Number of subjects: 63
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 18 mg SC
Number of subjects: 0
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 90 mg SC
Number of subjects: 0
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 300 mg SC
Number of subjects: 0
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 200 mg IV
Number of subjects: 0
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 600 mg IV
Number of subjects: 0
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 1200 mg IV
Number of subjects: 0
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 75 mg SC
Number of subjects: 0
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg SC
Number of subjects: 0
Study 31257614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (various doses)
Number of subjects: 0
Study 29912798 — intervention group
Group type: EXPERIMENTAL
Intervention: encenicline 1 mg twice daily
Number of subjects: 160
Study 29912798 — intervention group
Group type: EXPERIMENTAL
Intervention: encenicline 1 mg twice daily + NRT patch
Number of subjects: 160
Study 29912798 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 29912798 — intervention group
Group type: COMPARATOR
Intervention: placebo + NRT patch
Number of subjects: 160
Study 29912798 — intervention group
Group type: EXPERIMENTAL
Intervention: encenicline alone
Number of subjects: 160
Study 29912798 — intervention group
Group type: EXPERIMENTAL
Intervention: encenicline plus placebo patch
Number of subjects: 160
Study 26821699 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min guided warm-up using a bronchoscopy simulator
Number of subjects: 33
Study 26821699 — intervention group
Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 33
Study 24469546 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) group
Number of subjects: 180
Study 24469546 — intervention group
Group type: COMPARATOR
Intervention: Minimum Intervention (MI) group
Number of subjects: 180
Study 23197664 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSC transfusions
Number of subjects: 43
Study 23197664 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 43
Study 20221834 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive anterolateral approach
Number of subjects: 38
Study 20221834 — intervention group
Group type: COMPARATOR
Intervention: Modified direct lateral approach
Number of subjects: 38
Study 17667331 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational coformulation of EFV/FTC/TDF (test)
Number of subjects: 48
Study 17667331 — intervention group
Group type: COMPARATOR
Intervention: Commercially available individual dosage forms (reference treatment)
Number of subjects: 48
Study 15780109 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamin supplementation (1 mg of folic acid, 10 mg pyridoxal 5'-phosphate, and 6 µg of vitamin B12)
Number of subjects: 804
Study 15780109 — intervention group
Group type: COMPARATOR
Intervention: Dietary protein intake
Number of subjects: 804
Study 12208584 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 1572
Study 12208584 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 1572
Study 10221213 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix)
Number of subjects: 0
Study 10221213 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (buserelin)
Number of subjects: 0
Study 7797602 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg/day, oral)
Number of subjects: 55
Study 7797602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2355822 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck cooling
Number of subjects: 10
Study 2355822 — intervention group
Group type: COMPARATOR
Intervention: No neck cooling (control)
Number of subjects: 10
Study 759664 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 0
Study 759664 — intervention group
Group type: COMPARATOR
Intervention: Simple mastectomy followed by radiotherapy
Number of subjects: 0
Study 759664 — intervention group
Group type: COMPARATOR
Intervention: Wide excision followed by radiotherapy
Number of subjects: 0
Study 759664 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer treatment
Number of subjects: 0
Study 31957177 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 16
Study 31071131 — intervention group
Group type: EXPERIMENTAL
Intervention: NorVold Abuse Questionnaire (NorAQ) for emotional violence
Number of subjects: 1503
Study 31071131 — intervention group
Group type: EXPERIMENTAL
Intervention: NorVold Abuse Questionnaire (NorAQ) for sexual and/or physical violence
Number of subjects: 1503
Study 28763451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care program delivered by trained practice nurses over one year, consisting of watchful waiting, guided self-help, problem solving treatment, and referral to the general practitioner.
Number of subjects: 236
Study 28763451 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 236
Study 28763451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care program (intervention).
Number of subjects: 236
Study 26469750 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (30 mg DHA/kg/d)
Number of subjects: 51
Study 26469750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 23953830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 30
Study 23953830 — intervention group
Group type: COMPARATOR
Intervention: Conventional venography
Number of subjects: 30
Study 22035986 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGET (trauma affect regulation: guide for education and therapy)
Number of subjects: 146
Study 22035986 — intervention group
Group type: COMPARATOR
Intervention: PCT (present centered therapy)
Number of subjects: 146
Study 22035986 — intervention group
Group type: COMPARATOR
Intervention: WL (wait-list)
Number of subjects: 146
Study 18957532 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin daily for 8 weeks
Number of subjects: 20
Study 18957532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17276670 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1.5% with epinephrine 1:200000
Number of subjects: 80
Study 17276670 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1.5% with epinephrine 1:200000 and 8.4% sodium bicarbonate
Number of subjects: 80
Study 17276670 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1.5% with 8.4% sodium bicarbonate
Number of subjects: 80
Study 15531767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril at a target dose of 4 mg per day
Number of subjects: 8290
Study 15531767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8290
Study 11309014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 108
Study 11309014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg
Number of subjects: 108
Study 11309014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 108
Study 11309014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 and 0.9 mg/kg
Number of subjects: 108
Study 9444014 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 25 mg single dose
Number of subjects: 315
Study 9444014 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 50 mg single dose
Number of subjects: 315
Study 9444014 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 75 mg single dose
Number of subjects: 315
Study 9444014 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 100 mg twice daily for 3 days
Number of subjects: 315
Study 9444014 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg single dose
Number of subjects: 315
Study 7878597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0
Study 7878597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 0
Study 7878597 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, buspirone, doxepin
Number of subjects: 0
Study 3550555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic perfusion (HP) alone
Number of subjects: 76
Study 3550555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic perfusion (HP) with amputation
Number of subjects: 76
Study 3550555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic antiblastic perfusion (HAP) followed by amputation
Number of subjects: 76
Study 3550555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic antiblastic perfusion (HAP) followed by 'en bloc' resection and bone reconstruction
Number of subjects: 76
Study 29036300 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisource exchangeability models (MEMs)
Number of subjects: 0
Study 27002108 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily + MTX
Number of subjects: 109
Study 27002108 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg twice daily (monotherapy)
Number of subjects: 109
Study 27002108 — intervention group
Group type: COMPARATOR
Intervention: MTX + placebo (MTX monotherapy)
Number of subjects: 109
Study 24645942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemicraniectomy
Number of subjects: 112
Study 24645942 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment in the intensive care unit (control group)
Number of subjects: 112
Study 15829527 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (2000 IU daily)
Number of subjects: 769
Study 15829527 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (10 mg daily)
Number of subjects: 769
Study 15829527 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 769
Study 12366541 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint with transcutaneous electric nerve stimulation (TENS)
Number of subjects: 24
Study 12366541 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 9914551 — intervention group
Group type: EXPERIMENTAL
Intervention: Live teleconsultation with LBCO and RBCO
Number of subjects: 45
Study 9914551 — intervention group
Group type: COMPARATOR
Intervention: Delayed teleconsultation with DBCO
Number of subjects: 45
Study 7554523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 2 x 5 mg daily (normotensive group)
Number of subjects: 246
Study 7554523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 2 x 10 mg - 2 x 20 mg daily (hypertensive group)
Number of subjects: 246
Study 7554523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normotensive group)
Number of subjects: 246
Study 7554523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hypertensive group)
Number of subjects: 246
Study 7554523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (hypertensive group)
Number of subjects: 246
Study 7554523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (normotensive group)
Number of subjects: 246
Study 2188758 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tabulation of cine coronary angiograms
Number of subjects: 0
Study 2188758 — intervention group
Group type: COMPARATOR
Intervention: Cine coronary angiography
Number of subjects: 0
Study 2188758 — intervention group
Group type: COMPARATOR
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 0
Study 2188758 — intervention group
Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 0
Study 7356905 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (200 mg)
Number of subjects: 24
Study 7356905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (300 mg)
Number of subjects: 24
Study 7356905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30935539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-curcumin supplementation (80 mg for 8 weeks)
Number of subjects: 80
Study 28473614 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 63
Study 28473614 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training and Healthy Diet (RT-HD)
Number of subjects: 63
Study 28473614 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 63
Study 26280593 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater quantity of alcohol consumed the prior day
Number of subjects: 274
Study 26280593 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe hangover symptoms
Number of subjects: 274
Study 26280593 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger drinkers
Number of subjects: 274
Study 26280593 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater hangover severity
Number of subjects: 274
Study 23441798 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse adhesive (Solobond M)
Number of subjects: 24
Study 23441798 — intervention group
Group type: COMPARATOR
Intervention: All-in-one adhesive (Futurabond NR)
Number of subjects: 24
Study 21973199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate/pravastatin combination therapy
Number of subjects: 248
Study 21973199 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin monotherapy
Number of subjects: 248
Study 18584924 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised counselling with regular follow-up (n=24)
Number of subjects: 53
Study 18584924 — intervention group
Group type: COMPARATOR
Intervention: Standard care treatment (generic education only) (n=23)
Number of subjects: 53
Study 16029879 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task (complex emotion-based learning)
Number of subjects: 1
Study 12612505 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 140
Study 12612505 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy (subgroup with negative findings)
Number of subjects: 140
Study 12612505 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy (subgroup with positive findings)
Number of subjects: 140
Study 10838741 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal (group A)
Number of subjects: 88
Study 10838741 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug therapy without change (group B)
Number of subjects: 88
Study 9327823 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (30 seconds duration, 5 days per week for 6 weeks)
Number of subjects: 93
Study 9327823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 93
Study 8255478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (Ro 40-7592) administered in combination with levodopa/carbidopa
Number of subjects: 10
Study 8255478 — intervention group
Group type: COMPARATOR
Intervention: Control group (levodopa/carbidopa without tolcapone)
Number of subjects: 10
Study 2877570 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at bedtime
Number of subjects: 1031
Study 2877570 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice daily
Number of subjects: 1031
Study 2877570 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice daily
Number of subjects: 1031
Study 2877570 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 1031
Study 29752611 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 29752611 — intervention group
Group type: COMPARATOR
Intervention: Mild-warm moxibustion (Mox)
Number of subjects: 60
Study 26997218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine and hydrotalcite (starting 3 days before CE)
Number of subjects: 148
Study 26997218 — intervention group
Group type: COMPARATOR
Intervention: 250 mL 20% mannitol and 1 L 0.9% saline orally at 20:00 hours on the day before and at 05:00 hours on the day of CE and 20 mL simethicone 30 min before CE
Number of subjects: 148
Study 24359760 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced supervision of health workers
Number of subjects: 36
Study 24359760 — intervention group
Group type: COMPARATOR
Intervention: Routine supervision of health workers
Number of subjects: 36
Study 24359760 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced supervision
Number of subjects: 36
Study 24359760 — intervention group
Group type: COMPARATOR
Intervention: Routine supervision
Number of subjects: 36
Study 22444242 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel dose-response models considering spatial distribution of radiation dose
Number of subjects: 63
Study 22444242 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimising dose to the lateral and cranial component of the human parotid gland
Number of subjects: 63
Study 22444242 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of the sub-mandibular gland
Number of subjects: 63
Study 20534288 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily everolimus administration
Number of subjects: 23
Study 20534288 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily everolimus regimen
Number of subjects: 23
Study 20534288 — intervention group
Group type: COMPARATOR
Intervention: Both groups (once-daily and twice-daily)
Number of subjects: 23
Study 18441332 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare parenting program
Number of subjects: 0
Study 16088114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU ergocalciferol daily
Number of subjects: 96
Study 16088114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 12533495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Display (BD) during exciting VDT tasks
Number of subjects: 7
Study 12533495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Display (BD) during boring VDT tasks
Number of subjects: 7
Study 12533495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Display (BD) with exciting VDT tasks
Number of subjects: 7
Study 12533495 — intervention group
Group type: COMPARATOR
Intervention: Dark Display (DD) during exciting VDT tasks
Number of subjects: 7
Study 12533495 — intervention group
Group type: COMPARATOR
Intervention: Dark Display (DD) during boring VDT tasks
Number of subjects: 7
Study 10577294 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (years)
Number of subjects: 9105
Study 10577294 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific 6-month mortality rates
Number of subjects: 9105
Study 10577294 — intervention group
Group type: COMPARATOR
Intervention: Aggressiveness of care
Number of subjects: 9105
Study 8754325 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg slow release verapamil once daily
Number of subjects: 20
Study 8754325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1864092 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir, 800 mg 5 times daily
Number of subjects: 46
Study 6749352 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times a day for 6 months
Number of subjects: 1433
Study 6749352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1433
Study 31281989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training with blood flow restriction (LL-BFR)
Number of subjects: 15
Study 31281989 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (HL-RT)
Number of subjects: 15
Study 27980128 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonothrombolysis (CEST)
Number of subjects: 183
Study 27980128 — intervention group
Group type: COMPARATOR
Intervention: Sham CEST
Number of subjects: 183
Study 24995659 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical GON block with 10 mg dexamethasone + 40 mg lidocaine (5 mL volume)
Number of subjects: 30
Study 24995659 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcompartmental GON block with 10 mg dexamethasone + 40 mg lidocaine + nonionic iodine contrast + saline (5, 10, or 15 mL volume)
Number of subjects: 30
Study 24995659 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical GON block
Number of subjects: 30
Study 24995659 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcompartmental GON block
Number of subjects: 30